Scleroderma Organ Screening

Скринінг ураження легень, нирок і серця при системному склерозі.

Current Stage

—

—

Pulmonary risk

—

Renal crisis risk

—

Cardiac risk

—

Screening freq.

—

Disease duration (years)5

Skin involvementLimited

Low risk indicator

Moderate risk indicator

High risk indicator

Active screening test

Scroll for details

Screening for Interstitial Lung Disease

Placeholder lead: PFT and HRCT catch early fibrosis before symptoms appear.

~45%: ILD prevalence (placeholder stat)
6–12 mo: PFT interval (placeholder stat)
FVC drop: HRCT trigger (placeholder stat)
DLCO: Key test (placeholder stat)

PFT and HRCT basics

Placeholder: spirometry and diffusion capacity track early lung fibrosis.

Placeholder insight: annual PFT is the frontline screening test.

Echocardiographic PH Screening

Placeholder lead: echo estimates pulmonary pressure to catch PH early.

~15%: PH prevalence (placeholder stat)
Annual: Echo interval (placeholder stat)
RHC: Confirm test (placeholder stat)
PASP: Key marker (placeholder stat)

Echo-based PH detection

Placeholder: tricuspid regurgitant jet velocity estimates PASP.

Placeholder insight: right heart catheterization confirms diagnosis.

Blood Pressure and Creatinine Monitoring

Placeholder lead: renal crisis risk peaks early in diffuse disease.

0–4 yr: Peak window (placeholder stat)
Daily: BP self-check (placeholder stat)
ACE-i: Key drug class (placeholder stat)
Cr rise: Warning sign (placeholder stat)

Renal crisis warning signs

Placeholder: new hypertension plus rising creatinine signals crisis.

Placeholder insight: early ACE inhibitor use improves outcomes.

ECG and Echo Cardiac Screening

Placeholder lead: myocardial fibrosis and arrhythmia need routine screening.

~25%: Cardiac involvement (placeholder stat)
Annual: ECG interval (placeholder stat)
Cardiac MRI: Imaging option (placeholder stat)
Diffuse skin: Risk factor (placeholder stat)

Detecting cardiac fibrosis

Placeholder: ECG and echo screen for conduction and wall changes.

Placeholder insight: cardiac MRI detects subclinical fibrosis.

Composite Multi-Organ Risk Overview

Placeholder lead: combining organ risks sets a personalized screening plan.

3: Organs tracked (placeholder stat)
PFT/Echo/BP: Tests combined (placeholder stat)
Risk-based: Review interval (placeholder stat)
Early detection: Goal (placeholder stat)

Putting it together

Placeholder: combined risk score sets screening frequency and priority.

Placeholder insight: multidisciplinary follow-up improves survival.